Sanna Bastiano
SEC CIK 1829069 · EDGAR
BoughtSold
Most active insiders at ACET, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 10% | $5.00M | $674.8K |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 10% | $1.60M | — |
| 3 | Aftab Blake | CSO | — | — |
| 4 | Healey Don | CTO | — | — |
| 5 | Harvey Brian Nicholas | CFO | — | — |
| 6 | Schor Chen | Pres, CEO, Dir | — | — |
Sanna Bastiano made no open-market trades at ACET in the last 12 months.
Transactions 33
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-02 | 2023-06-01 | ACET | Adicet Bio, Inc. | Sanna Bastiano | Dir | A - Grant | $0.00 | +5,900 | 5,900 | New | $0 |
| M | 2023-05-09 | 2023-05-05+ | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $350.00 | -3,272 | 34.9K | -9% | -$1.15M |
| M | 2023-05-04 | 2023-05-02+ | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $350.71 | -4,403 | 35.3K | -11% | -$1.54M |
| M | 2023-04-14 | 2023-04-12 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $326.70 | -7,567 | 42.3K | -15% | -$2.47M |
| M | 2023-04-06 | 2023-04-04 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $315.81 | -522 | 47.3K | -1% | -$164.9K |
| 2023-04-04 | 2023-03-31 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $313.74 | -1,466 | 47.8K | -3% | -$459.9K | |
| M | 2023-03-20 | 2023-03-16 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.59 | -2,746 | 49.5K | -5% | -$825.4K |
| 2023-02-28 | 2023-02-24 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $289.12 | -3,970 | 52.0K | -7% | -$1.15M | |
| 2023-02-22 | 2023-02-17 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $292.85 | -3,750 | 56.0K | -6% | -$1.10M | |
| M | 2023-02-16 | 2023-02-14 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.39 | -2,181 | 60.0K | -4% | -$655.2K |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $297.58 | -5,242 | 62.0K | -8% | -$1.56M |
| 2023-02-14 | 2023-02-13 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.39 | -113 | 61.9K | -0.2% | -$33.9K | |
| M | 2023-02-03 | 2023-02-01 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | A - Grant | $0.00 | +29.3K | 47.1K | +164% | $0 |
| 2023-02-02 | 2023-01-31 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $325.00 | -106 | 38.0K | -0.3% | -$34.5K | |
| M | 2022-11-03 | 2022-11-02 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $312.64 | -320 | 38.2K | -0.8% | -$100.0K |
| 2022-11-03 | 2022-11-01 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $312.84 | -768 | 38.4K | -2% | -$240.3K | |
| M | 2022-10-20 | 2022-10-18 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $300.31 | -1,791 | 39.5K | -4% | -$537.9K |
| 2022-08-03 | 2022-08-01 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $276.62 | -766 | 41.0K | -2% | -$211.9K | |
| M | 2022-05-18 | 2022-05-16 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $252.83 | -45 | 41.7K | -0.1% | -$11.4K |
| 2022-05-06 | 2022-05-04 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $275.09 | -36 | 41.7K | -0.1% | -$9,903 | |
| M | 2022-05-04 | 2022-05-02 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $259.16 | -320 | 41.9K | -0.8% | -$82.9K |
| 2022-05-03 | 2022-04-29 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $276.17 | -766 | 42.0K | -2% | -$211.5K | |
| M | 2022-04-08 | 2022-04-07 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $276.18 | -561 | 42.8K | -1% | -$154.9K |
| M | 2022-04-06 | 2022-04-04+ | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $274.10 | -3,725 | 46.8K | -7% | -$1.02M |
| 2022-04-05 | 2022-04-01 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $263.09 | -1,344 | 47.1K | -3% | -$353.6K | |
| 2022-03-21 | 2022-03-17 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $250.06 | -2,122 | 48.4K | -4% | -$530.6K | |
| 2022-02-22 | 2022-02-17 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $232.51 | -3,439 | 50.5K | -6% | -$799.6K | |
| 2022-02-14 | 2022-02-10 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $237.74 | -979 | 54.0K | -2% | -$232.7K | |
| 2022-02-03 | 2022-02-01 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $243.64 | -526 | 56.0K | -0.9% | -$128.2K | |
| M | 2022-02-03 | 2022-02-02 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $250.98 | -1,040 | 55.3K | -2% | -$261.0K |
| M | 2022-02-03 | 2022-02-01 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | A - Grant | $0.00 | +23.9K | 56.5K | +73% | $0 |
| 2021-11-03 | 2021-11-01 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $185.07 | -766 | 32.6K | -2% | -$141.8K | |
| 2021-08-03 | 2021-07-30 | VRTX | Vertex Pharmaceuticals | Sanna Bastiano | EVP, Cell, Genetic Therapies | F - Tax | $200.39 | -766 | 33.3K | -2% | -$153.5K |
Purchase Sale Sale after option exercise All abbreviations